TGFB1 and systemic sclerosis: Evidence from an in vivo murine model of SSc demonstrates that STAT3 inhibition suppresses TGF-β myofibroblast differentiation, reduces collagen production and profibrotic gene expression, and improves skin fibrosis [144].